Company record · updated August 5, 2026
KWOL Acquisition Inc. (dba Worldwide Clinical Trials): 1 valuation observation from SEC filings
Every row below names the filing it came from. Coverage for this company runs December 31, 2023 to December 31, 2023.
1observations
1source filings
1verified rows
2023-12-31most recent as-of date
Source rails for this company: BDC equity mark (1).
Reported by 1 filer: Blue Owl Technology Income Corp..
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2023-12-31 | price per share | 10,003.1546 USD | Blue Owl Technology Income Corp. | VERIFIED | Common stock: 317 units / fair value 3,171 (declared thousands) | 0001869453-25-000011 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.